BUDGET IMPACT ANALYSIS OF THE PATIENT BLOOD MANAGEMENT FROM A FRENCH NATIONAL PAYER AND HOSPITAL PERSPECTIVES IN FRANCE

Author(s)

Vasilescu L1, Champs F1, Durand-Zaleski I2, Delahaye D3, Dussart C4, Paubel P5, Lasocki S6
1Iqvia, Courbevoie, France, 2Unité de recherche clinique en économie de la santé d’Ile-de-France, Paris, France, 3APHM HOPITAL Ste-Marguerite, Marseille, France, 4Lyon 1 University, Lyon, 69, France, 5General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP); Health Law Institute, INSERM UMR S 1145, Paris Descartes ; Faculté of pharmacy, Paris Descartes University, Sorbonne Paris Cité, Paris, France, 6CHU d’Angers, Angers, France

OBJECTIVES: Patient Blood Management (PBM) is a "patient-focused, evidence based and systematic approach for optimizing the management of patients and transfusion of blood products to ensure high quality and effective patient care". It permits to mitigate the potential negative outcomes related to anemia pre- and postoperatively. PBM is based on three pillars: optimize the patients’ blood, minimize blood loss and manage patients’ anemia.

METHODS: This Budget Impact Model compares two scenarios “current clinical practice” (i.e. without PBM) and “with PBM implementation” in five surgical therapy areas (orthopedic surgery, cardiac surgery, urologic surgery, vascular surgery, digestive surgery) and from two different perspectives (Hospital and French National Payer). The model is based on an analysis of the French national hospital database (PMSI) which provides estimates of eligible population, the proportion of patients transfused, the average length of stay the proportion of anemic patients and the cost of hospitalization. These data were supplemented by the literature and validated by an expert consensus.

RESULTS: More than 2.2 million of patients could benefit from the implementation of a PBM program for the five surgical areas. From a hospital perspective, for the orthopedic surgery area that benefits roughly 1.3 million patients, the cost impact is estimated at - 427 € per patient. Indeed, PBM implementation could allow for a 17 % reduction of the mean length of stay and 77 % reduction in the total of transfused patients.

CONCLUSIONS: The implementation of a national PBM program in France will represent an improvement in health outcome and a high added value for public health thanks to reductions in transfusion rates and lengths of stay. Indeed, PBM contributes to good practices to diagnose and treat anemia, minimize blood loss and avoid unnecessary transfusions while improving patient outcomes, health standard quality of care as well as costs.

Conference/Value in Health Info

2018-11, ISPOR Europe 2018, Barcelona, Spain

Value in Health, Vol. 21, S3 (October 2018)

Code

PSY45

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis

Disease

Systemic Disorders/Conditions

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×